Literature DB >> 8160617

Beneficial effects of a single dose of quinapril on left ventricular performance in chronic mitral regurgitation.

H R Schön1, G Schröter, H Blömer, A Schömig.   

Abstract

To evaluate the effect of a single dose of the angiotensin-converting enzyme inhibitor quinapril on left ventricular (LV) performance and size in patients with moderate to severe chronic mitral regurgitation (MR), 12 patients with angiographically proven isolated MR grade II to III and no evidence of coronary artery disease were studied. In all patients a baseline right heart catheterization and simultaneous radionuclide angiogram were performed at rest and during supine exercise (maximum 100 W) as well as 2 hours after oral administration of 10 mg of quinapril. Quinapril reduced heart rate slightly and lowered mean blood pressure at rest and during maximal exercise (p < 0.05). Systemic vascular resistance at rest was decreased from 1,484 +/- 505 to 1,150 +/- 427 dynes s cm-5 and with maximal exercise from 999 +/- 455 to 734 +/- 395 dynes s cm-5 (p < 0.005). Pulmonary capillary arterial pressure at rest decreased from 13 +/- 6 to 10 +/- 4 mm Hg (p = 0.01) and during maximal exercise from 29 +/- 10 to 20 +/- 7 mm Hg (p = 0.001). LV end-diastolic volume at rest (146 +/- 26 ml/m2) decreased after administration of quinapril to 128 +/- 24 ml/m2 (p = 0.001) and was also reduced during exercise (p = 0.001). LV end-systolic volume decreased from 63 +/- 43 to 49 +/- 35 ml/m2 at rest (p = 0.001) and with maximal exercise from 56 +/- 49 to 44 +/- 39 ml/m2 (p < 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8160617     DOI: 10.1016/0002-9149(94)90882-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  3 in total

1.  Role of vasodilators in regurgitant valve disease.

Authors:  Artur Evangelista; Pilar Tornos; Antonia Sambola; Gaieta Permayer-Miralda
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-12

Review 2.  Quinapril: a further update of its pharmacology and therapeutic use in cardiovascular disorders.

Authors:  Christine R Culy; Blair Jarvis
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 3.  Management decisions in valvular heart disease: the role of radionuclide-based assessment of ventricular function and performance.

Authors:  J S Borer; D Wencker; C Hochreiter
Journal:  J Nucl Cardiol       Date:  1996 Jan-Feb       Impact factor: 5.952

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.